Spark Therapeutics’ Luxturna gains EU approval as first gene therapy for inherited retinal disease

In a significant breakthrough for treating inherited vision loss, Pennsylvania-based Spark Therapeutics has received European Commission (EC) approval for its pioneering gene therapy, Luxturna (voretigene ... Read More